Sivik Global Healthcare LLC Has $5.70 Million Stock Position in Baxter International Inc. (NYSE:BAX)

Sivik Global Healthcare LLC raised its stake in shares of Baxter International Inc. (NYSE:BAX - Free Report) by 50.0% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 150,000 shares of the medical instruments supplier's stock after purchasing an additional 50,000 shares during the period. Baxter International accounts for approximately 2.4% of Sivik Global Healthcare LLC's investment portfolio, making the stock its 17th biggest position. Sivik Global Healthcare LLC's holdings in Baxter International were worth $5,696,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. First PREMIER Bank bought a new position in shares of Baxter International in the 3rd quarter worth about $25,000. Innealta Capital LLC purchased a new position in Baxter International during the 2nd quarter valued at about $27,000. LRI Investments LLC purchased a new stake in shares of Baxter International during the first quarter valued at about $39,000. Fortitude Family Office LLC acquired a new stake in Baxter International during the 3rd quarter worth about $38,000. Finally, Versant Capital Management Inc boosted its position in Baxter International by 974.2% during the second quarter. Versant Capital Management Inc now owns 1,332 shares of the medical instruments supplier's stock worth $45,000 after purchasing an additional 1,208 shares in the last quarter. 90.19% of the stock is owned by institutional investors.

Baxter International Price Performance

Shares of Baxter International stock traded down $0.51 during trading hours on Thursday, hitting $32.12. The company's stock had a trading volume of 251,374 shares, compared to its average volume of 4,053,071. The company has a market cap of $16.39 billion, a PE ratio of 163.21, a PEG ratio of 11.44 and a beta of 0.60. Baxter International Inc. has a 12-month low of $32.01 and a 12-month high of $44.01. The business has a 50 day moving average price of $37.13 and a two-hundred day moving average price of $35.94. The company has a debt-to-equity ratio of 1.35, a quick ratio of 0.91 and a current ratio of 1.40.

Baxter International (NYSE:BAX - Get Free Report) last released its quarterly earnings data on Friday, November 8th. The medical instruments supplier reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.78 by $0.02. The firm had revenue of $3.85 billion for the quarter, compared to analyst estimates of $3.85 billion. Baxter International had a net margin of 0.77% and a return on equity of 18.19%. The business's quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.68 earnings per share. Analysts expect that Baxter International Inc. will post 2.33 earnings per share for the current fiscal year.

Baxter International Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 2nd. Investors of record on Friday, November 29th will be paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 2.12%. The ex-dividend date of this dividend is Friday, November 29th. Baxter International's dividend payout ratio is currently 580.03%.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. JPMorgan Chase & Co. decreased their target price on shares of Baxter International from $44.00 to $42.00 and set a "neutral" rating on the stock in a research report on Wednesday, August 7th. StockNews.com cut shares of Baxter International from a "buy" rating to a "hold" rating in a research note on Monday. The Goldman Sachs Group boosted their price objective on shares of Baxter International from $36.00 to $40.00 and gave the stock a "neutral" rating in a research report on Thursday, August 8th. Citigroup increased their price target on Baxter International from $38.00 to $40.00 and gave the stock a "neutral" rating in a research note on Tuesday, October 1st. Finally, Stifel Nicolaus decreased their target price on Baxter International from $46.00 to $38.00 and set a "buy" rating for the company in a report on Monday. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat.com, Baxter International currently has an average rating of "Hold" and an average price target of $40.91.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.